JP2011508742A5 - - Google Patents

Download PDF

Info

Publication number
JP2011508742A5
JP2011508742A5 JP2010540873A JP2010540873A JP2011508742A5 JP 2011508742 A5 JP2011508742 A5 JP 2011508742A5 JP 2010540873 A JP2010540873 A JP 2010540873A JP 2010540873 A JP2010540873 A JP 2010540873A JP 2011508742 A5 JP2011508742 A5 JP 2011508742A5
Authority
JP
Japan
Prior art keywords
formulation
concentration
rvwf
salt
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010540873A
Other languages
English (en)
Japanese (ja)
Other versions
JP5784907B2 (ja
JP2011508742A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/088201 external-priority patent/WO2009086400A2/en
Publication of JP2011508742A publication Critical patent/JP2011508742A/ja
Publication of JP2011508742A5 publication Critical patent/JP2011508742A5/ja
Application granted granted Critical
Publication of JP5784907B2 publication Critical patent/JP5784907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010540873A 2007-12-28 2008-12-23 組換え型ｖｗｆ製剤 Active JP5784907B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1741807P 2007-12-28 2007-12-28
US61/017,418 2007-12-28
US1788107P 2007-12-31 2007-12-31
US61/017,881 2007-12-31
PCT/US2008/088201 WO2009086400A2 (en) 2007-12-28 2008-12-23 Recombinant vwf formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014111341A Division JP2014159479A (ja) 2007-12-28 2014-05-29 組換え型ｖｗｆ製剤

Publications (3)

Publication Number Publication Date
JP2011508742A JP2011508742A (ja) 2011-03-17
JP2011508742A5 true JP2011508742A5 (enExample) 2015-01-22
JP5784907B2 JP5784907B2 (ja) 2015-09-24

Family

ID=40591819

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010540873A Active JP5784907B2 (ja) 2007-12-28 2008-12-23 組換え型ｖｗｆ製剤
JP2014111341A Withdrawn JP2014159479A (ja) 2007-12-28 2014-05-29 組換え型ｖｗｆ製剤
JP2016112428A Pending JP2016164199A (ja) 2007-12-28 2016-06-06 組換え型ｖｗｆ製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014111341A Withdrawn JP2014159479A (ja) 2007-12-28 2014-05-29 組換え型ｖｗｆ製剤
JP2016112428A Pending JP2016164199A (ja) 2007-12-28 2016-06-06 組換え型ｖｗｆ製剤

Country Status (15)

Country Link
US (2) US20090192076A1 (enExample)
EP (2) EP2244814B1 (enExample)
JP (3) JP5784907B2 (enExample)
KR (2) KR20160091434A (enExample)
CN (2) CN101952016A (enExample)
AR (1) AR069989A1 (enExample)
AU (1) AU2008345135C1 (enExample)
BR (1) BRPI0821474B8 (enExample)
CA (1) CA2710762A1 (enExample)
ES (1) ES2887187T3 (enExample)
MX (1) MX2010007150A (enExample)
NZ (1) NZ586383A (enExample)
SG (2) SG187410A1 (enExample)
TW (3) TWI515006B (enExample)
WO (1) WO2009086400A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652782B2 (en) * 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
AU2008343745B2 (en) 2007-10-01 2012-05-10 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2244814B1 (en) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
US8546548B2 (en) 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
SG181628A1 (en) * 2009-12-22 2012-07-30 Celldex Therapeutics Inc Vaccine compositions
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
EP3158055B1 (en) * 2014-06-13 2019-09-11 CSL Limited Improved production of recombinant von willebrand factor in a bioreactor
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
CN113082349B (zh) 2016-06-27 2023-07-28 武田药品工业株式会社 注射器稳定装置
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
CN107966567B (zh) * 2017-11-21 2018-12-18 浙江夸克生物科技有限公司 一种触珠蛋白测定试剂盒
CA3094644A1 (en) * 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
EP4097145B1 (en) * 2020-01-30 2026-01-28 Leukocare Ag Reduction of adsorption
ES3040184T3 (en) * 2020-03-18 2025-10-29 Gi Innovation Inc Fusion protein preparation comprising il-2 and cd80 proteins
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
EP4490042A4 (en) 2022-03-08 2026-03-04 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA7972A (en) * 1877-10-05 Edward M. Lowdon Improvements in lamps
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
US5900476A (en) * 1986-05-30 1999-05-04 The Scripps Research Institute Therapeutic domains of van Willebrand factor
WO1993000107A1 (en) * 1991-06-20 1993-01-07 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic fragments of von willebrand factor
US5847086A (en) 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
US20010046487A1 (en) * 1994-12-30 2001-11-29 Roser Bruce J. Methods for loading platelets, stabilizing platelets for dry storage and compositions obtained thereby
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
DE69734247T2 (de) * 1996-07-19 2006-06-22 The Regents Of The University Of Michigan, Ann Arbor Für den von willebrand faktor der hunde kodierende dna und verfahren zu ihrer verwendung
SE9604296D0 (sv) 1996-11-22 1996-11-22 Astra Ab New pharmaceutical formulation of polypeptides
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6005007A (en) * 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
FR2772381B1 (fr) 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
EP1148063A1 (de) 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
DE10043124A1 (de) * 2000-08-31 2002-03-14 Max Delbrueck Centrum Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase
AU2001291653A1 (en) 2000-10-02 2002-04-15 Novo-Nordisk A/S Industrial-scale serum-free production of recombinant factor vii in mammalian cells
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
ES2363205T3 (es) 2002-06-21 2011-07-26 Novo Nordisk Health Care Ag Glicoformas del factor vii pegilado.
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
FR2861395B1 (fr) * 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
EP2311437A1 (en) * 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
DE102004044421B4 (de) * 2004-09-14 2010-06-24 Biotest Ag Verfahren zur Trennung eines von Willebrand Faktors mit einer spezifischen VWF-Aktivität von wenigstens 50 E/mg VWF-Antigen von einem von Willebrand Faktor mit niedriger Aktivität und Verwendung von Hydroxylapatit dafür
AU2005322067B8 (en) 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
GB0509443D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbents for factor VIII and von willebrand's factor
EP2264162A1 (en) * 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
EP2377554A1 (en) * 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
ES2391657T3 (es) * 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
WO2008015187A1 (en) 2006-08-01 2008-02-07 Telefonaktiebolaget Lm Ericsson (Publ) User preferences in interactive personal television
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US20100137211A1 (en) * 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
EP2150264A4 (en) * 2007-04-26 2014-09-24 Bayer Healthcare Llc STABILIZATION OF LIQUID SOLUTIONS OF A RECOMBINANT PROTEIN FOR FROZEN STORAGE
PL2167117T3 (pl) 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
EP2244814B1 (en) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
CN104013569A (zh) * 2008-10-15 2014-09-03 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
EP2352515A4 (en) * 2008-11-03 2012-04-25 Bayer Healthcare Llc METHOD FOR TREATING HEMOPHILIA
NZ594698A (en) * 2009-02-05 2013-08-30 Pierre Philippart Method and means for producing tissues and tissues obtained

Similar Documents

Publication Publication Date Title
NZ586383A (en) Recombinant vwf formulations
TWI223597B (en) Stable concentrated insulin preparations for pulmonary delivery
JP6525471B2 (ja) ヘプシジン類似体及びその使用
RU2010103995A (ru) Бифункциональные слитые белки альфа-меланоцитостимулирующего гормона (альф-msh) и атриального натрийуретического белка (anp) и их применение при гипертонии и остром повреждении почек
KR102319868B1 (ko) 재조합 vwf의 투여에 의한 응고 질환의 치료
NZ592704A (en) Lyophilized recombinant von willebrand factor (rVWF) formulation comprising buffering agents, amino acids, stabilising agents and surfactants
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
HRP20140616T1 (hr) Peptidni analog oksintomodulina
JP2011511753A5 (enExample)
JP2010527607A5 (enExample)
FI3248610T3 (fi) Fgf21-mutantit ja niiden käyttö
JP2004537581A5 (enExample)
KR20110086583A (ko) 제8 인자 제형
JP2009102374A (ja) 可溶性トロンボモジュリン含有製剤
WO1997002832A1 (fr) Preparations lyophilisees de hgf
AU2024204870A1 (en) Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin
JP2019509041A5 (enExample)
RU2012157399A (ru) Пептиды в качестве активных агентов для стабилизации биологических барьеров
KR100351495B1 (ko) α-인터페론BDBB를포함하는수성액상제제
AU2014237111B2 (en) Recombinant factor VIII formulations
ES2383994T3 (es) Formulación líquida de hormona del crecimiento
US20220016211A1 (en) Fgf-21 conjugate formulations
RU2011133224A (ru) Новые фармацевтические композиции
Shi et al. Site-specific PEGylation of human growth hormone by mutated sortase A
US8735352B2 (en) Adsorbent for blood coagulation factor or cell adhesion factor and method for purifying the factor